BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18982511)

  • 1. The return of investment of translational research in inflammatory dermatoses.
    van de Kerkhof PC
    J Dermatolog Treat; 2008; 19(6):317. PubMed ID: 18982511
    [No Abstract]   [Full Text] [Related]  

  • 2. Adalimumab vs. etanercept in psoriasis.
    Downs AM
    Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
    [No Abstract]   [Full Text] [Related]  

  • 3. Switching biologics for psoriasis.
    Ormerod AD
    Br J Dermatol; 2010 Oct; 163(4):667-9. PubMed ID: 20854399
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-TNF-alpha therapy in childhood pustular psoriasis.
    Pereira TM; Vieira AP; Fernandes JC; Antunes H; Basto AS
    Dermatology; 2006; 213(4):350-2. PubMed ID: 17135745
    [No Abstract]   [Full Text] [Related]  

  • 5. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
    Rallis E; Verros CD
    Dermatol Online J; 2011 Apr; 17(4):14. PubMed ID: 21549089
    [No Abstract]   [Full Text] [Related]  

  • 6. [What is the impact of the new clinical trial data? What are the lessons for patient management?].
    Passeron T; Boulinguez S
    Ann Dermatol Venereol; 2010 May; 137(5 Suppl 1):11-5. PubMed ID: 20510174
    [No Abstract]   [Full Text] [Related]  

  • 7. [European and British recommendations on the role of biologic interventions in moderate to severe psoriasis].
    Bachelez H; Battistella M
    Ann Dermatol Venereol; 2011 Apr; 138(2 Suppl 2):H14-7. PubMed ID: 21703457
    [No Abstract]   [Full Text] [Related]  

  • 8. Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
    Carlesimo M; La Pietra M; Arcese A; Di Russo PP; Mari E; Gamba A; Orsini D; Camplone G
    Int J Dermatol; 2012 Oct; 51(10):1234-6. PubMed ID: 22416995
    [No Abstract]   [Full Text] [Related]  

  • 9. A scientific debate: key clinical questions in the management of psoriasis.
    Stingl G
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():1. PubMed ID: 22758910
    [No Abstract]   [Full Text] [Related]  

  • 10. Advertisements for TNF Inhibitors.
    Med Lett Drugs Ther; 2008 Nov; 50(1299):89. PubMed ID: 19008788
    [No Abstract]   [Full Text] [Related]  

  • 11. [Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis].
    Moreno-Ramírez D
    Actas Dermosifiliogr; 2011 May; 102(4):241-3. PubMed ID: 21481332
    [No Abstract]   [Full Text] [Related]  

  • 12. Eosinophilia during psoriasis treatment with TNF antagonists.
    Malisiewicz B; Murer C; Pachlopnik Schmid J; French LE; Schmid-Grendelmeier P; Navarini AA
    Dermatology; 2011; 223(4):311-5. PubMed ID: 22301393
    [No Abstract]   [Full Text] [Related]  

  • 13. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
    Woolf RT; Smith CH; Robertson K; Barker JN
    Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
    [No Abstract]   [Full Text] [Related]  

  • 14. Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors.
    Egnatios G; Warthan MM; Pariser R; Hood AF
    J Drugs Dermatol; 2008 Oct; 7(10):975-7. PubMed ID: 19112764
    [No Abstract]   [Full Text] [Related]  

  • 15. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept.
    Field S; Regan AO; Sheahan K; Collins P
    Clin Exp Dermatol; 2010 Oct; 35(7):795-6. PubMed ID: 20831604
    [No Abstract]   [Full Text] [Related]  

  • 16. Newer treatment options for patients with moderate-to-severe psoriatic disease.
    Roebuck HL
    Nurse Pract; 2006 Aug; 31(8):5-6,11. PubMed ID: 16966969
    [No Abstract]   [Full Text] [Related]  

  • 17. [Long-term psoriasis treatment].
    Jullien D; Battistella M
    Ann Dermatol Venereol; 2011 Feb; 138(2 Suppl 1):H15-8. PubMed ID: 21396519
    [No Abstract]   [Full Text] [Related]  

  • 18. Is there a benefit from using a subsequent anti-TNF α medication in psoriasis patients who failed their first or second anti-TNF α agent?
    Alsharqi A; Parslew R; Dever B; Arslanian V
    Australas J Dermatol; 2012 May; 53(2):e45-7. PubMed ID: 22571585
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term management of erythrodermic psoriasis with anti-TNF agents.
    Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
    Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriasis options abound. Ongoing research on Enbrel and Raptiva supports their use in psoriasis treatment.
    Krueger GG
    Health News; 2004 Jan; 10(1):10-1. PubMed ID: 15002383
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.